Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases
Adjuvant systemic chemotherapy (CTx) is widely administered in patients with colorectal liver metastases (CRLM). Histopathological growth patterns (HGPs) are an independent prognostic factor for survival after complete resection. This study evaluates whether HGPs can predict the effectiveness of adj...
Gespeichert in:
| Veröffentlicht in: | Clinical & experimental metastasis 2020-10, Vol.37 (5), p.593-605 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 605 |
|---|---|
| container_issue | 5 |
| container_start_page | 593 |
| container_title | Clinical & experimental metastasis |
| container_volume | 37 |
| creator | Buisman, Florian E. van der Stok, Eric P. Galjart, Boris Vermeulen, Peter B. Balachandran, Vinod P. Coebergh van den Braak, Robert R. J. Creasy, John M. Höppener, Diederik J. Jarnagin, William R. Kingham, T. Peter Nierop, Pieter M. H. Sadot, Eran Shia, Jinru Groot Koerkamp, Bas Grünhagen, Dirk J. D’Angelica, Michael Verhoef, Cornelis |
| description | Adjuvant systemic chemotherapy (CTx) is widely administered in patients with colorectal liver metastases (CRLM). Histopathological growth patterns (HGPs) are an independent prognostic factor for survival after complete resection. This study evaluates whether HGPs can predict the effectiveness of adjuvant CTx in patients with resected CRLM. Two main types of HGPs can be distinguished; the desmoplastic type and the non-desmoplastic type. Uni- and multivariable analyses for overall survival (OS) and disease-free survival (DFS) were performed, in both patients treated with and without preoperative chemotherapy. A total of 1236 patients from two tertiary centers (Memorial Sloan Kettering Cancer Center, New York, USA; Erasmus MC Cancer Institute, Rotterdam, The Netherlands) were included (period 2000–2016). A total of 656 patients (53.1%) patients received preoperative chemotherapy. Adjuvant CTx was only associated with a superior OS in non-desmoplastic patients that had not been pretreated (adjusted hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.37–0.73, p |
| doi_str_mv | 10.1007/s10585-020-10048-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7497305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2425898305</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-b743bad028ac02b255e4139436a280d45f76c88d53bb289a735fa9968c1500473</originalsourceid><addsrcrecordid>eNp9kcuO1DAQRS0EYpqBH2CBLLFhE_AzdjZIaDQwSCOxgbXlOE7HTRI3ttOt_gJ-m2oyDI8FkiU_6tStKl-EnlPymhKi3mRKpJYVYaSCu9DV8QHaUKl4pZiqH6INYTWriG70BXqS844ApJR-jC44qxtKtdqg7zchl7i3ZYhj3AZnR7xN8VgGDG_Fpzljm3Eb4mTTV59wHxO23W452LngfMrFT8FhN_gplsEnuz_hMJ9zg59LxscASsln74rvsIMaCY5QZAwHUJt8sRmWz0_Ro96O2T-72y_Rl_fXn69uqttPHz5evbutnFCiVK0SvLUdYdo6wlompReUN4LXlmnSCdmr2mndSd62TDdWcdnbpqm1o_I8Pb9Eb1fd_dJOvnPQZbKj2acAA55MtMH8HZnDYLbxYJRoFCcSBF7dCaT4bfG5mClk58fRzj4u2TDBJPz4ir78B93FJc0wHlCC1pJRSoBiK-VSzDn5_r4ZSszZZ7P6bMBn89Nnc4SkF3-OcZ_yy1gA-ApkCM1bn37X_o_sD78qt_E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2441652110</pqid></control><display><type>article</type><title>Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Buisman, Florian E. ; van der Stok, Eric P. ; Galjart, Boris ; Vermeulen, Peter B. ; Balachandran, Vinod P. ; Coebergh van den Braak, Robert R. J. ; Creasy, John M. ; Höppener, Diederik J. ; Jarnagin, William R. ; Kingham, T. Peter ; Nierop, Pieter M. H. ; Sadot, Eran ; Shia, Jinru ; Groot Koerkamp, Bas ; Grünhagen, Dirk J. ; D’Angelica, Michael ; Verhoef, Cornelis</creator><creatorcontrib>Buisman, Florian E. ; van der Stok, Eric P. ; Galjart, Boris ; Vermeulen, Peter B. ; Balachandran, Vinod P. ; Coebergh van den Braak, Robert R. J. ; Creasy, John M. ; Höppener, Diederik J. ; Jarnagin, William R. ; Kingham, T. Peter ; Nierop, Pieter M. H. ; Sadot, Eran ; Shia, Jinru ; Groot Koerkamp, Bas ; Grünhagen, Dirk J. ; D’Angelica, Michael ; Verhoef, Cornelis</creatorcontrib><description>Adjuvant systemic chemotherapy (CTx) is widely administered in patients with colorectal liver metastases (CRLM). Histopathological growth patterns (HGPs) are an independent prognostic factor for survival after complete resection. This study evaluates whether HGPs can predict the effectiveness of adjuvant CTx in patients with resected CRLM. Two main types of HGPs can be distinguished; the desmoplastic type and the non-desmoplastic type. Uni- and multivariable analyses for overall survival (OS) and disease-free survival (DFS) were performed, in both patients treated with and without preoperative chemotherapy. A total of 1236 patients from two tertiary centers (Memorial Sloan Kettering Cancer Center, New York, USA; Erasmus MC Cancer Institute, Rotterdam, The Netherlands) were included (period 2000–2016). A total of 656 patients (53.1%) patients received preoperative chemotherapy. Adjuvant CTx was only associated with a superior OS in non-desmoplastic patients that had not been pretreated (adjusted hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.37–0.73, p < 0.001), and not in desmoplastic patients (adjusted HR 1.78, 95% CI 0.75–4.21, p = 0.19). In pretreated patients no significant effect of adjuvant CTx was observed, neither in the desmoplastic group (adjusted HR 0.83, 95% CI 0.49–1.42, p = 0.50) nor in the non-desmoplastic group (adjusted HR 0.96, 95% CI 0.71–1.29, p = 0.79). Similar results were found for DFS, with a superior DFS in non-desmoplastic patients treated with adjuvant CTx (HR 0.71, 95% CI 0.55–0.93, p < 0.001) that were not pretreated. Adjuvant CTx seems to improve OS and DFS after resection of non-desmoplastic CRLM. However, this effect was only observed in patients that were not treated with chemotherapy.</description><identifier>ISSN: 0262-0898</identifier><identifier>EISSN: 1573-7276</identifier><identifier>DOI: 10.1007/s10585-020-10048-w</identifier><identifier>PMID: 32691187</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer Research ; Chemotherapy ; Chemotherapy, Adjuvant - mortality ; Colorectal cancer ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - surgery ; Confidence intervals ; Female ; Follow-Up Studies ; Growth patterns ; Hematology ; Hepatectomy - mortality ; Humans ; Liver ; Liver Neoplasms - drug therapy ; Liver Neoplasms - secondary ; Liver Neoplasms - surgery ; Male ; Metastases ; Metastasis ; Middle Aged ; Oncology ; Prognosis ; Research Paper ; Retrospective Studies ; Surgical Oncology ; Survival ; Survival Rate</subject><ispartof>Clinical & experimental metastasis, 2020-10, Vol.37 (5), p.593-605</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-b743bad028ac02b255e4139436a280d45f76c88d53bb289a735fa9968c1500473</citedby><cites>FETCH-LOGICAL-c474t-b743bad028ac02b255e4139436a280d45f76c88d53bb289a735fa9968c1500473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10585-020-10048-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10585-020-10048-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32691187$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buisman, Florian E.</creatorcontrib><creatorcontrib>van der Stok, Eric P.</creatorcontrib><creatorcontrib>Galjart, Boris</creatorcontrib><creatorcontrib>Vermeulen, Peter B.</creatorcontrib><creatorcontrib>Balachandran, Vinod P.</creatorcontrib><creatorcontrib>Coebergh van den Braak, Robert R. J.</creatorcontrib><creatorcontrib>Creasy, John M.</creatorcontrib><creatorcontrib>Höppener, Diederik J.</creatorcontrib><creatorcontrib>Jarnagin, William R.</creatorcontrib><creatorcontrib>Kingham, T. Peter</creatorcontrib><creatorcontrib>Nierop, Pieter M. H.</creatorcontrib><creatorcontrib>Sadot, Eran</creatorcontrib><creatorcontrib>Shia, Jinru</creatorcontrib><creatorcontrib>Groot Koerkamp, Bas</creatorcontrib><creatorcontrib>Grünhagen, Dirk J.</creatorcontrib><creatorcontrib>D’Angelica, Michael</creatorcontrib><creatorcontrib>Verhoef, Cornelis</creatorcontrib><title>Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases</title><title>Clinical & experimental metastasis</title><addtitle>Clin Exp Metastasis</addtitle><addtitle>Clin Exp Metastasis</addtitle><description>Adjuvant systemic chemotherapy (CTx) is widely administered in patients with colorectal liver metastases (CRLM). Histopathological growth patterns (HGPs) are an independent prognostic factor for survival after complete resection. This study evaluates whether HGPs can predict the effectiveness of adjuvant CTx in patients with resected CRLM. Two main types of HGPs can be distinguished; the desmoplastic type and the non-desmoplastic type. Uni- and multivariable analyses for overall survival (OS) and disease-free survival (DFS) were performed, in both patients treated with and without preoperative chemotherapy. A total of 1236 patients from two tertiary centers (Memorial Sloan Kettering Cancer Center, New York, USA; Erasmus MC Cancer Institute, Rotterdam, The Netherlands) were included (period 2000–2016). A total of 656 patients (53.1%) patients received preoperative chemotherapy. Adjuvant CTx was only associated with a superior OS in non-desmoplastic patients that had not been pretreated (adjusted hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.37–0.73, p < 0.001), and not in desmoplastic patients (adjusted HR 1.78, 95% CI 0.75–4.21, p = 0.19). In pretreated patients no significant effect of adjuvant CTx was observed, neither in the desmoplastic group (adjusted HR 0.83, 95% CI 0.49–1.42, p = 0.50) nor in the non-desmoplastic group (adjusted HR 0.96, 95% CI 0.71–1.29, p = 0.79). Similar results were found for DFS, with a superior DFS in non-desmoplastic patients treated with adjuvant CTx (HR 0.71, 95% CI 0.55–0.93, p < 0.001) that were not pretreated. Adjuvant CTx seems to improve OS and DFS after resection of non-desmoplastic CRLM. However, this effect was only observed in patients that were not treated with chemotherapy.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant - mortality</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Confidence intervals</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Growth patterns</subject><subject>Hematology</subject><subject>Hepatectomy - mortality</subject><subject>Humans</subject><subject>Liver</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Research Paper</subject><subject>Retrospective Studies</subject><subject>Surgical Oncology</subject><subject>Survival</subject><subject>Survival Rate</subject><issn>0262-0898</issn><issn>1573-7276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kcuO1DAQRS0EYpqBH2CBLLFhE_AzdjZIaDQwSCOxgbXlOE7HTRI3ttOt_gJ-m2oyDI8FkiU_6tStKl-EnlPymhKi3mRKpJYVYaSCu9DV8QHaUKl4pZiqH6INYTWriG70BXqS844ApJR-jC44qxtKtdqg7zchl7i3ZYhj3AZnR7xN8VgGDG_Fpzljm3Eb4mTTV59wHxO23W452LngfMrFT8FhN_gplsEnuz_hMJ9zg59LxscASsln74rvsIMaCY5QZAwHUJt8sRmWz0_Ro96O2T-72y_Rl_fXn69uqttPHz5evbutnFCiVK0SvLUdYdo6wlompReUN4LXlmnSCdmr2mndSd62TDdWcdnbpqm1o_I8Pb9Eb1fd_dJOvnPQZbKj2acAA55MtMH8HZnDYLbxYJRoFCcSBF7dCaT4bfG5mClk58fRzj4u2TDBJPz4ir78B93FJc0wHlCC1pJRSoBiK-VSzDn5_r4ZSszZZ7P6bMBn89Nnc4SkF3-OcZ_yy1gA-ApkCM1bn37X_o_sD78qt_E</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Buisman, Florian E.</creator><creator>van der Stok, Eric P.</creator><creator>Galjart, Boris</creator><creator>Vermeulen, Peter B.</creator><creator>Balachandran, Vinod P.</creator><creator>Coebergh van den Braak, Robert R. J.</creator><creator>Creasy, John M.</creator><creator>Höppener, Diederik J.</creator><creator>Jarnagin, William R.</creator><creator>Kingham, T. Peter</creator><creator>Nierop, Pieter M. H.</creator><creator>Sadot, Eran</creator><creator>Shia, Jinru</creator><creator>Groot Koerkamp, Bas</creator><creator>Grünhagen, Dirk J.</creator><creator>D’Angelica, Michael</creator><creator>Verhoef, Cornelis</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201001</creationdate><title>Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases</title><author>Buisman, Florian E. ; van der Stok, Eric P. ; Galjart, Boris ; Vermeulen, Peter B. ; Balachandran, Vinod P. ; Coebergh van den Braak, Robert R. J. ; Creasy, John M. ; Höppener, Diederik J. ; Jarnagin, William R. ; Kingham, T. Peter ; Nierop, Pieter M. H. ; Sadot, Eran ; Shia, Jinru ; Groot Koerkamp, Bas ; Grünhagen, Dirk J. ; D’Angelica, Michael ; Verhoef, Cornelis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-b743bad028ac02b255e4139436a280d45f76c88d53bb289a735fa9968c1500473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant - mortality</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Confidence intervals</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Growth patterns</topic><topic>Hematology</topic><topic>Hepatectomy - mortality</topic><topic>Humans</topic><topic>Liver</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Research Paper</topic><topic>Retrospective Studies</topic><topic>Surgical Oncology</topic><topic>Survival</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buisman, Florian E.</creatorcontrib><creatorcontrib>van der Stok, Eric P.</creatorcontrib><creatorcontrib>Galjart, Boris</creatorcontrib><creatorcontrib>Vermeulen, Peter B.</creatorcontrib><creatorcontrib>Balachandran, Vinod P.</creatorcontrib><creatorcontrib>Coebergh van den Braak, Robert R. J.</creatorcontrib><creatorcontrib>Creasy, John M.</creatorcontrib><creatorcontrib>Höppener, Diederik J.</creatorcontrib><creatorcontrib>Jarnagin, William R.</creatorcontrib><creatorcontrib>Kingham, T. Peter</creatorcontrib><creatorcontrib>Nierop, Pieter M. H.</creatorcontrib><creatorcontrib>Sadot, Eran</creatorcontrib><creatorcontrib>Shia, Jinru</creatorcontrib><creatorcontrib>Groot Koerkamp, Bas</creatorcontrib><creatorcontrib>Grünhagen, Dirk J.</creatorcontrib><creatorcontrib>D’Angelica, Michael</creatorcontrib><creatorcontrib>Verhoef, Cornelis</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical & experimental metastasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buisman, Florian E.</au><au>van der Stok, Eric P.</au><au>Galjart, Boris</au><au>Vermeulen, Peter B.</au><au>Balachandran, Vinod P.</au><au>Coebergh van den Braak, Robert R. J.</au><au>Creasy, John M.</au><au>Höppener, Diederik J.</au><au>Jarnagin, William R.</au><au>Kingham, T. Peter</au><au>Nierop, Pieter M. H.</au><au>Sadot, Eran</au><au>Shia, Jinru</au><au>Groot Koerkamp, Bas</au><au>Grünhagen, Dirk J.</au><au>D’Angelica, Michael</au><au>Verhoef, Cornelis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases</atitle><jtitle>Clinical & experimental metastasis</jtitle><stitle>Clin Exp Metastasis</stitle><addtitle>Clin Exp Metastasis</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>37</volume><issue>5</issue><spage>593</spage><epage>605</epage><pages>593-605</pages><issn>0262-0898</issn><eissn>1573-7276</eissn><abstract>Adjuvant systemic chemotherapy (CTx) is widely administered in patients with colorectal liver metastases (CRLM). Histopathological growth patterns (HGPs) are an independent prognostic factor for survival after complete resection. This study evaluates whether HGPs can predict the effectiveness of adjuvant CTx in patients with resected CRLM. Two main types of HGPs can be distinguished; the desmoplastic type and the non-desmoplastic type. Uni- and multivariable analyses for overall survival (OS) and disease-free survival (DFS) were performed, in both patients treated with and without preoperative chemotherapy. A total of 1236 patients from two tertiary centers (Memorial Sloan Kettering Cancer Center, New York, USA; Erasmus MC Cancer Institute, Rotterdam, The Netherlands) were included (period 2000–2016). A total of 656 patients (53.1%) patients received preoperative chemotherapy. Adjuvant CTx was only associated with a superior OS in non-desmoplastic patients that had not been pretreated (adjusted hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.37–0.73, p < 0.001), and not in desmoplastic patients (adjusted HR 1.78, 95% CI 0.75–4.21, p = 0.19). In pretreated patients no significant effect of adjuvant CTx was observed, neither in the desmoplastic group (adjusted HR 0.83, 95% CI 0.49–1.42, p = 0.50) nor in the non-desmoplastic group (adjusted HR 0.96, 95% CI 0.71–1.29, p = 0.79). Similar results were found for DFS, with a superior DFS in non-desmoplastic patients treated with adjuvant CTx (HR 0.71, 95% CI 0.55–0.93, p < 0.001) that were not pretreated. Adjuvant CTx seems to improve OS and DFS after resection of non-desmoplastic CRLM. However, this effect was only observed in patients that were not treated with chemotherapy.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>32691187</pmid><doi>10.1007/s10585-020-10048-w</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0262-0898 |
| ispartof | Clinical & experimental metastasis, 2020-10, Vol.37 (5), p.593-605 |
| issn | 0262-0898 1573-7276 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7497305 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomedical and Life Sciences Biomedicine Cancer Cancer Research Chemotherapy Chemotherapy, Adjuvant - mortality Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Colorectal Neoplasms - surgery Confidence intervals Female Follow-Up Studies Growth patterns Hematology Hepatectomy - mortality Humans Liver Liver Neoplasms - drug therapy Liver Neoplasms - secondary Liver Neoplasms - surgery Male Metastases Metastasis Middle Aged Oncology Prognosis Research Paper Retrospective Studies Surgical Oncology Survival Survival Rate |
| title | Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T10%3A39%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histopathological%20growth%20patterns%20as%20biomarker%20for%20adjuvant%20systemic%20chemotherapy%20in%20patients%20with%20resected%20colorectal%20liver%20metastases&rft.jtitle=Clinical%20&%20experimental%20metastasis&rft.au=Buisman,%20Florian%20E.&rft.date=2020-10-01&rft.volume=37&rft.issue=5&rft.spage=593&rft.epage=605&rft.pages=593-605&rft.issn=0262-0898&rft.eissn=1573-7276&rft_id=info:doi/10.1007/s10585-020-10048-w&rft_dat=%3Cproquest_pubme%3E2425898305%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2441652110&rft_id=info:pmid/32691187&rfr_iscdi=true |